Company / Capital Expenditures
Roivant Sciences Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.4M
FY2025
5-year range
$1.4M / $17.4M
FY2021-FY2025
Trend
-69.9%
vs FY2024
Sector context
#106 of 194
Health Care
What the data says
At $1M, Roivant Sciences's capital expenditures ranks #106 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 6 years, ranging from $1M in FY2025 to $17M in FY2021.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -25.0%.
Remained stable around $1M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -38.0%
- 5-Year CAGR
- -25.0%
- 10-Year CAGR
- -
Sector benchmark
#106 of 194 in Health CareTop 55% of 194This company $1.4M Sector average $117.5M
▼
-98.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -25.0%, indicating a declining trend.
- In FY2025, capital expenditures decreased 69.9% year-over-year.
- Ranks #106 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | -69.9% |
| FY2024 | $4.6M | +232.8% |
| FY2023 | $1.4M | -76.2% |
| FY2022 | $5.8M | -66.7% |
| FY2021 | $17.4M | +200.3% |
| FY2020 | $5.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026